Sanofi (NASDAQ:SNY) Shares Sold by Intrust Bank NA

Intrust Bank NA decreased its holdings in Sanofi (NASDAQ:SNY) by 11.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,615 shares of the company’s stock after selling 3,076 shares during the period. Intrust Bank NA’s holdings in Sanofi were worth $1,174,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Rise Advisors LLC increased its position in shares of Sanofi by 98.4% in the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after purchasing an additional 251 shares during the last quarter. Salem Investment Counselors Inc. acquired a new stake in shares of Sanofi during the 4th quarter worth about $27,000. Venturi Wealth Management LLC increased its stake in Sanofi by 163.5% in the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after purchasing an additional 332 shares during the last quarter. Farmers & Merchants Trust Co of Chambersburg PA lifted its position in shares of Sanofi by 115.6% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock worth $37,000 after buying an additional 400 shares during the last quarter. Finally, CNB Bank acquired a new position in shares of Sanofi in the 3rd quarter valued at $39,000. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Price Performance

Shares of SNY stock traded up $0.61 during midday trading on Tuesday, reaching $49.70. 127,854 shares of the company traded hands, compared to its average volume of 1,987,639. The firm’s 50 day simple moving average is $47.77 and its two-hundred day simple moving average is $48.28. The firm has a market cap of $125.72 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 1.48 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. Sanofi has a 1-year low of $42.63 and a 1-year high of $55.93.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a net margin of 10.52% and a return on equity of 19.69%. On average, equities research analysts expect that Sanofi will post 4.09 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a dividend of $1.478 per share. This represents a yield of 2.98%. The ex-dividend date is Thursday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is 69.35%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SNY. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Morgan Stanley assumed coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective on the stock. Finally, TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.